U.S. taxpayers may have overpaid for EpiPen by as much as $1.27 billion from 2006 through 2016, U.S. Sen. Chuck Grassley said Wednesday, citing an estimate from the Department of Health and Human Services Office of Inspector General. The Iowa Republican said that’s far more than the $465 million that EpiPen maker Mylan agreed to in settlement negotiations with the Justice Department.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News